Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

422 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial.
Lafaurie M, Collin F, Bentata M, Garré M, Leport C, Levy Y, Goujard C, Chêne G, Molina JM; ALIZE Study Group. Lafaurie M, et al. Among authors: leport c. J Antimicrob Chemother. 2008 Nov;62(5):1122-9. doi: 10.1093/jac/dkn309. Epub 2008 Jul 28. J Antimicrob Chemother. 2008. PMID: 18662943 Clinical Trial.
CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study.
Wittkop L, Arsandaux J, Trevino A, Schim van der Loeff M, Anderson J, van Sighem A, Böni J, Brun-Vezinet F, Soriano V, Boufassa F, Brockmeyer N, Calmy A, Dabis F, Jarrin I, Dorrucci M, Duque V, Fätkenheuer G, Zangerle R, Ferrer E, Porter K, Judd A, Sipsas NV, Lambotte O, Shepherd L, Leport C, Morrison C, Mussini C, Obel N, Ruelle J, Schwarze-Zander C, Sonnerborg A, Teira R, Torti C, Valadas E, Colin C, Friis-Møller N, Costagliola D, Thiebaut R, Chene G, Matheron S; COHERE in EuroCoord and ACHIeV2e Study Group. Wittkop L, et al. Among authors: leport c. J Antimicrob Chemother. 2017 Oct 1;72(10):2869-2878. doi: 10.1093/jac/dkx210. J Antimicrob Chemother. 2017. PMID: 29091198 Free article.
Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants.
Delagreverie HM, Grude M, Lambert-Niclot S, Nere ML, Jadand C, Leport C, Raffi F, Ghislain M, Goujard C, Meyer L, Calvez V, Katlama C, Flandre P, Barin F, Delaugerre C. Delagreverie HM, et al. Among authors: leport c. J Antimicrob Chemother. 2019 May 1;74(5):1389-1394. doi: 10.1093/jac/dkz004. J Antimicrob Chemother. 2019. PMID: 30690509 Clinical Trial.
Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.
Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts. Krastinova E, et al. PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Print 2013. PLoS One. 2013. PMID: 23936509 Free PMC article.
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.
De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro MM, Günthard HF, Wittkop L, Kordossis T, Garcia F, Castagna A, Cozzi-Lepri A, Churchill D, De Wit S, Brockmeyer NH, Imaz A, Mussini C, Obel N, Perno CF, Roca B, Reiss P, Schülter E, Torti C, van Sighem A, Zangerle R, Descamps D; CHAIN and COHERE in EuroCoord. De Luca A, et al. J Antimicrob Chemother. 2016 May;71(5):1352-60. doi: 10.1093/jac/dkv465. Epub 2016 Jan 28. J Antimicrob Chemother. 2016. PMID: 26825119 Free PMC article.
A highly virulent variant of HIV-1 circulating in the Netherlands.
Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M, Ong SH, Zhao L, Bonsall D, de Cesare M, MacIntyre-Cockett G, Abeler-Dörner L, Albert J, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C; Netherlands ATHENA HIV Observational Cohort†; BEEHIVE Collaboration†. Wymant C, et al. Science. 2022 Feb 4;375(6580):540-545. doi: 10.1126/science.abk1688. Epub 2022 Feb 3. Science. 2022. PMID: 35113714 Free article.
Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients.
Le Moing V, Chêne G, Leport C, Lewden C, Duran S, Garré M, Masquelier B, Dupon M, Raffi F; Antiprotéases Cohorte (APROCO) Study Group. Le Moing V, et al. Among authors: leport c. Clin Infect Dis. 2002 Jan 15;34(2):239-47. doi: 10.1086/324354. Epub 2001 Dec 4. Clin Infect Dis. 2002. PMID: 11740714
Health-related quality of life after 1 year of highly active antiretroviral therapy.
Carrieri P, Spire B, Duran S, Katlama C, Peyramond D, François C, Chêne G, Lang JM, Moatti JP, Leport C; APROCO Study Group. Carrieri P, et al. Among authors: leport c. J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):38-47. doi: 10.1097/00126334-200301010-00006. J Acquir Immune Defic Syndr. 2003. PMID: 12514412 Clinical Trial.
422 results